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Abstract
TheSRY(sexdeterminingregion Y)-box11(SOX11)gene,located onchromosome2p25,encodesforatranscriptionfactorthat
isinvolvedintissueremodelingduringembryogenesisandiscrucialforneurogenesis.TheroleforSOX11inhematopoiesishas
not yet been defined. Two genes under direct control of SOX11 are the class- III b-tubulin gene (TUBB3) in neural cells and the
transcription factor TEA domain family member 2 (TEAD2) in neural and mesenchymal progenitor cells. Normal, mature
lymphocytes lack SOX11 but express SOX4, another member of the same group of SOX transcription factors. We and others
recently identified SOX11 as aberrantly expressed in mantle cell lymphoma (MCL). Since SOX11 is variably expressed in MCL it
may not be essential for tumorigenesis, but may carry prognostic information. Currently, no specific functional effects have
been linked to SOX11 expression in MCL and it is not known which genes are under influence of SOX11 in lymphoma. In this
study we found variable expression of SOX11, SOX4 and SOX12 mRNA in mantle cell lymphoma cell lines. Downregulation of
SOX11 expression by siRNA verified that SOX11 controlled the expression of the gene TUBB3 in the MCL cell line Granta 519.
Furthermore we identified, by global gene expression analysis, 26 new target genes influenced by siRNA SOX11
downmodulation. Among these genes, DBN1, SETMAR and HIG2 were found to be significantly correlated to SOX11
expression in two cohorts of primary mantle cell lymphomas. Chromatin immunoprecipitation (ChIP) analysis showed that
these genes are direct targets of the SOX11 protein. In spite of almost complete downregulation of the SOX11 protein no
significanteffects on Granta519 cell proliferationor survival in short term in vitro experiments was found. In summary we have
identified a number of genes influenced by SOX11 expression in MCL cell lines and primary MCL. Among these genes, DBN1,
SETMAR and HIG2 are direct transcriptional targets of the SOX11 protein.
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Introduction
The SRY (sex determining region Y)-box 11 (SOX11)
transcription factor was recently discovered as a new marker in
mantle cell lymphoma (MCL), expressed in both cyclin D1 positive
and negative cases [1,2,3,4]. SOX11, located on chromosome
2p25, is a member of the SOX gene family and was discovered in
1995 [5]. Approximately 20 SOX genes have been identified and
they are divided into eight subgroups according to the degree of
similarity within and outside the high mobility domain (HMG) [6].
All SOX genes have unique and specific expression patterns and
they control cell survival, proliferation and differentiation in
numerous processes during embryogenesis (reviewed in [7]).
SOX11, together with SOX4 and SOX12, belongs to the SOXC
group, sharing a high degree of homology both in the HMG
domain and the C-terminal transactivation domain [8]. In the
mouse, Sox11 is important for organ development, neurogenesis,
neural cell survival and neurite outgrowth [8,9,10] [11] while Sox4
is crucial for B lymphocyte differentiation [12]. Upregulated
SOX11 has been found in brain tumors and in ovarian carcinoma,
where it has been associated to tumorigenesis and clinical outcome
[13,14,15,16,17]. The recently reported aberrant expression of
SOX11 in most MCL [1,2,3,4,18,19] raises the hypothesis that
SOX11 may have a role in the pathogenesis of MCL.
MCL is characterized by enhanced cell proliferation, impaired
cell death pathways and reduced response to DNA damaging
agents and is therefore difficult to treat [20]. These features can
only be partly explained by the t(11;14)(q13;q32) causing
dysregulation of cyclin D1 expression. While the t(11;14) is an
early event in the pathogenesis of most MCL other genetic events
are necessary for lymphoma development [21,22].
Theclass-IIIb-tubulin gene(TUBB3) isup-regulatedbySox11in
neural cells [8]. Using siRNA-mediated knockdown of SOX11 in
the MCL cell lines Granta 519 and JeKo, we found that TUBB3
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e14085wasinfluenced bySOX11alsoinMCL.Additionally,26geneswere
significantly downregulated upon SOX11 silencing in Granta 519.
Among these genes, drebrin 1 (DBN1), SET domain and mariner
transposase fusion gene (SETMAR) and hypoxia-inducible protein
2 (HIG2) expression correlated to SOX11 expression in a series of
SOX11 positive MCL [4]. We found a strong correlation between
SOX11 and DBN1, SETMAR and HIG2 expression in a recently
published study on SOX11 positive and negative MCL [19].
Furthermore, in MCL cell lines and primary MCL cells, DBN1
significantly correlated to SOX11 expression.
Results
Expression of SOXC Transcription Factors in MCL Cell
Lines – High Expression of SOX11 in Granta 519
SOX4, SOX11 and SOX12 may have partially overlapping
effects on transcriptional regulation [8]. We therefore investigated
the expression of the three SOXC transcription factors, SOX4,
SOX11 and SOX12 in the t(11;14) positive MCL cell lines Granta
519, Rec1, JeKo and JVM-2 (Figure 1). Granta 519, Rec1 and
JeKo expressed SOX11 mRNA and protein while JVM-2 was
negative for SOX11 expression (Figure 1). SOX4 and SOX12
protein expression could not be measured due to lack of
commercially available specific antibodies. The Granta 519 cell
line expressed high levels of SOX11 and very little SOX4 and
SOX12 and was therefore chosen for further studies.
Silencing of SOX11 in Granta 519 Modifies TUBB3
Expression
The effect of siRNA-inhibition of SOX11 in Granta 519 was
investigated using the S13312 siRNA. After 20 hours, the
expression of SOX11 mRNA decreased by approximately 85%
compared to cells treated with control siRNA (Figure 2A).
Downregulation of mRNA was stable between 12–48 hours (data
not shown). The SOX11 protein could not be detected at 20 hours
after SOX11 knock down (Figure 2B) and the protein levels
remained undetectable for 72 hours (data not shown). Similar
silencing effects were obtained by another SOX11 siRNA, S224667
(data not shown). TUBB3 has been shown to be regulated by Sox11
in non-hematopoietic cells [8]. We therefore investigated whether
SOX11 is able to regulate TUBB3 in Granta 519. 20 hours after
transfection with SOX11 siRNA the expression of TUBB3 was
reduced by 70% compared to negative control siRNA (Figure 2C).
Silencing of SOX11 Significantly Reduces the Expression
of 26 Genes
We next analyzed the effect of knock down of SOX11 on global
gene expression in Granta 519 cells. At the chosen time point,
20 hours after transfection, 26 genes were significantly downreg-
ulated in SOX11 siRNA treated cells compared to cells treated
with control siRNA at the chosen threshold (FDR,0.002,
FC$1.5 or FC#21.5) (Table 1). No upregulated genes were
found using this threshold.
SOX11 Expression Correlates to DBN1, SETMAR and HIG2
Expression in Two Independent MCL Cohorts
To test the generality of our findings we investigated how the
expression of the 26 downregulated genes correlated to SOX11
expression in 16 primary MCL, all positive for cyclin D1 and
SOX11 [4]. In addition to SOX11, nine of the 26 genes were
represented on the U133A chip used in this analysis. Of these,
HIG2, SETMAR and DBN1 were significantly correlated to
Figure 1. Expression of SOXC genes in MCL cell lines. Expression of SOX4 (A), SOX12 (B) and SOX11 (C) in the MCL cell lines Granta 519, JeKo,
Rec1 and JVM2 by quantitative RT- PCR. Granta 519 express high levels of SOX11 mRNA but low levels of the other SOXC genes while no SOX11
mRNA expression was detected in JVM2. (D) WB showed that Granta 519, JeKo and Rec1, but not JVM2, express SOX11 protein.
doi:10.1371/journal.pone.0014085.g001
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study, Fernandez et al. provided evidence for lack of SOX11
expression in leukemic MCL with indolent clinical course [19].
We therefore investigated possible correlation with SOX11 among
these MCL cases (GSE 16455). 19 of our 26 genes defined by
SOX11siRNA were represented in this data set. The expression of
15 genes of these genes was significantly correlated to SOX11
expression, including DBN1, SETMAR and HIG2 (Table 3).
Expression of SETMAR and DBN1 are Influenced by
SOX11 in vitro and SOX11 Expression Correlated to DBN1
in Primary MCL Cells
To validate the results of the gene expression analysis,
SETMAR and DBN1 were analysed by quantitative RT-PCR
in Granta 519 after SOX11 siRNA treatment. Both SETMAR
and DBN1 mRNA levels were significantly (p,0.001) reduced by
SOX11 downregulation in Granta 519 cells (Figure 3A). In
another MCL cell line, JeKo, SOX11 downregulation caused
similar reduction of TUBB3 and DBN1 levels but not of
SETMAR (Figure 3B). We also found a significant correlation
between the expression of SOX11 and DBN1 in primary MCL
cells (8 samples from 6 patients as described in Materials and
Methods and Table 4) and in the MCL cell lines Granta 519, Rec1
and JeKo (Figure 4).
DBN1, SETMAR, and HIG2 are Direct Targets of SOX11
Protein
To investigate whether DBN1, SETMAR and HIG2 are direct
targets of SOX11 protein, we performed chromatin immunopre-
cipitation (ChIP) assays on Granta 519 cells using two pairs of
primers for each gene as described in Material and Methods.
Granta 519 cells were cross-linked, and protein-DNA complexes
were immunoprecipitated using antibodies recognizing normal
rabbit IgG or anti-SOX11 antibody. We found that SOX11 was
significantly recruited to DBN1, SETMAR and HIG2 promoter
regions close to the transcription start site (TSS), but not to regions
2 kb distal to the TSS (DT) (Figure 5).
Discussion
The main finding of this study is the identification of 26 genes
influenced by SOX11 in MCL. SOX11 has critical roles in
embryonic neurogenesis and tissue remodeling [5,9,23,24]. It is
also required for neuron survival and neurite growth [25] but no
defined role in hematopoiesis has yet been shown.
The SOX11 protein belongs to the HMG box super family of
DNA-binding proteins which are highly conserved between
animals. They are involved in the regulation of such diverse
development processes as specification of early embryonic germ
layers [26,27], organ development and neurogenesis [28]. SOX11,
together with two other SOX family members SOX4 and SOX12,
belong to the same subgroup, SOXC. SOX4 is so far the only
gene in this family that has been found to have an important role
in lymphopoiesis. SOX4–null hematopoietic cells grafted into wild
type mice remain blocked at the pro-B cell stage [12]. Although
SOX11 is highly homologous to SOX4, its role in lymphopoiesis
remains unclear.
Recently, SOX11 was found to be aberrantly expressed in MCL
[1,2,3,4,18]. Importantly, approximately 10% of cyclin D1
positive MCL lack nuclear expression of SOX11 [2,4,19].
SOX11 is also expressed in subsets of Burkitt lymphomas,
lymphoblastic leukemias and hairy cell leukemias [1,3,18]. Thus,
expression of SOX11 in lymphoma seems independent of the
t(11;14) cyclin D1 translocation.
The possible role of the aberrant SOX11 expression in
lymphoma is unknown. Others have shown that SOX11 is needed
for the expression of pan-neuronal genes, including the Class- b-
tubulin gene TUBB3 (also named Tuj1). TUBB3 was the first gene
to be identified as a potential direct target of SOXC proteins. In
this study, we showed that SOX11 can modify the expression of
TUBB3 also in MCL.
By gene expression analysis using a very stringent threshold, we
identified 26 genes, all significantly downregulated, after SOX11
knockdown in MCL cells. Three of these genes were also found to
be significantly correlated to SOX11 expression levels in 16
SOX11 positive primary MCL samples from various tissues.
During the course of our study, Fernandez et al. published results
on MCL with leukemic, non-nodal presentation and a very
Figure 2. SOX11 silencing significantly reduces TUBB3 expres-
sion in the MCL cell line Granta 519. (A) Expression of SOX11 was
evaluated after transfection with either 100 pmol SOX11 siRNA or control
siRNA. The SOX11 mRNA level was measured by quantitative RT-PCR
20 hours after electroporation. Error bars show standard deviation of 4
independent experiments, ***p,0.001. (B) Western blots show downreg-
ulation of SOX11 protein in Granta 519 after SOX11 siRNA knockdown but
not in cells treated with control siRNA or in untransfected cells.
(C) Depletion of SOX11 protein significantly reduces TUBB3 expression.
Granta519cellsweretransfectedwithSOX11siRNAandTUBB3expression
was investigated by quantitative RT-PCR after 20 hours. ***P,0.001.
doi:10.1371/journal.pone.0014085.g002
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been misdiagnosed as other types of lymphomas. 15 of the 26
SOX11siRNA downregulated genes in Granta 519 were found to
be significantly correlated to SOX11 expression in the Fernandez
cohort, confirming our observations.
Prior to this study, Tubb3 and Tead2 were the only genes proven to
be directly regulated by Sox11 [8,9]. By chromatin immunoprecipi-
tation we showed direct binding of the SOX11 protein to the promoter
regions of the DBN1, SETMAR and HIG2 genes in MCL cells.
DBN1 and three other genes downregulated by SOX11
silencing, TMSB15A, TMSB15B and C5orf13 are actin binding
and involved in cell shape and motility. DBN1 encodes for the
actin binding protein drebrin 1 (developmentally regulated brain
protein), cloned in 1988 [29,30]. DBN1 was later shown to be is
involved in neurite formation and synaptic signalling (reviewed in
[31]) and to be downregulated in brains of Alzheimer patients
[32,33]. Drebrin is also expressed in epithelial cells of the stomach,
kidney, colon and in cell lines from fibroblasts and astrocytoma
[34]. Interestingly, drebrin is cleaved by caspase-6 [35], encoded
by another of the SOX11siRNA downregulated genes.TMSB15A
and TMSB15B encode for different isoforms of the actin binding
protein thymosin beta 15. Thymosin beta 15 promotes cell motility
and was discovered as highly upregulated in human breast,
prostate and colon cancer [36,37,38,39]. According to NCBI,
C5orf13 is coding for the protein P311, highly expressed in glioma
and involved in glioma cell migration through the reorganization
of the actin cytoskeleton [40]. Thus a number of genes involved in
cell shape and motility were downregulated by SOX11 siRNA
treatment of Granta 519 cells. We could, however, not detect any
significant change in shape or growth pattern of the cells after
siRNA treatment (data not shown).
SETMAR, HIG2 and HMGB3 could potentially influence cell
division and response to cytostatic treatment. SETMAR, also called
METNASE,is cooperating withtopoisomerase IIalpha indecoiling
of chromosomes during mitosis. Recent evidence in acute myeloid
leukemia suggests that SETMAR may confer resistance to the
topoisomerase II alpha inhibitor VP-16 [41,42]. The HMGB3
protein belongs to the high mobility group of proteins and may, as
shown for other HMG proteins, play a role in DNA replication and
transcription. Hmgb3 is highly expressed in hematopoietic stem
cells [43]. Recent experiment in mice indicate that Hmgb3
downregulation is associated with increased Wnt-signalling, more
rapid renewal of stem cells and fewer lymphoid and myeloid
progenitor cells [44]. We therefore investigated a possible influence
on cell proliferation or cell survival in vitro after SOX11 knock-down
by siRNA. In these short term experiments, we did however not
Table 1. Differently expressed genes after SOX11 knockdown by siRNA in Granta 519 cells
#.
probe set ID gene_assignment p-value* Fold-Change*
8174189 NM_021992//TMSB15A//thymosin beta 15a//Xq21.33-q22.3 6.9064e-010 23.94
8040070 NM_003108//SOX11//SRY (sex determining region Y)-box 11//2p25 4.3570e-009 23.05
8110589 NM_015455//CNOT6//CCR4-NOT transcription complex, subunit 6//5q35.3 7.7295e-009 21.52
7963054 NM_006009//TUBA1A//tubulin, alpha 1a//12q12-q14 2.2166e-008 22.04
8117640 NM_025231//ZSCAN16//zinc finger and SCAN domain containing 16//6p22.1 3.8797e-008 21.55
8047127 NM_001130158//MYO1B//myosin IB//2q12-q34 4.4570e-008 22.43
8113504 NM_004772//C5orf13//chromosome 5 open reading frame 13//5q22.1 1.6184e-007 21.78
8077370 NM_006515//SETMAR//SET domain and mariner transposase fusion gene//3p26.1 2.4819e-007 21.58
8069880 NM_003253//TIAM1//T-cell lymphoma invasion and metastasis 1//21q22.1|21q22 2.6924e-007 21.71
8169073 NM_194324//TMSB15B//thymosin beta 15B//Xq22.2 2.7046e-007 21.70
7925550 NM_001126//ADSS//adenylosuccinate synthase//1cen-q12 2.7195e-007 21.72
8005458 NM_001040078//LGALS9C//lectin, galactoside-binding, soluble, 9C//17p11.2/ 4.1908e-007 21.69
8170468 NM_005342//HMGB3//high-mobility group box 3//Xq28 4.9152e-007 21.53
8013450 NM_001042685//LGALS9B//lectin, galactoside-binding, soluble, 9B//17p11.2 8.6597e-007 21.71
8177222 NM_013230//CD24//CD24 molecule//6q21 9.3981e-007 22.20
8102311 NM_001226//CASP6//caspase 6, apoptosis-related cysteine peptidase//4q25 1.1825e-006 21.58
8091103 NM_006286//TFDP2//transcription factor Dp-2 (E2F dimerization partner 2) 1.2042e-006 21.61
7930882 NM_207009//FAM45A//family with sequence similarity 45, member A//10q25 1.2641e-006 21.51
8127109 NM_016513//ICK//intestinal cell (MAK-like) kinase//6p12.1 3.0653e-006 21.67
8116051 NM_080881//DBN1//drebrin 1//5q35.3 3.4139e-006 21.71
8005809 NM_009587//LGALS9//lectin, galactoside-binding, soluble, 9//17q11.2//396 3.8368e-006 21.86
8135915 NM_013332//C7orf68//chromosome 7 open reading frame 68//7q32.1 4.6540e-006 22.24
8150186 NM_024787//RNF122//ring finger protein 122//8p12 6.2295e-006 21.85
8075263 NM_003634//NIPSNAP1//nipsnap homolog 1 (C. elegans)//22q12.2 6.4654e-006 21.56
8074780 NM_013313//YPEL1//yippee-like 1 (Drosophila)//22q11.2 2.6161e-005 21.99
7930181 NM_020682//AS3MT//arsenic (+3 oxidation state) methyltransferase//10q24.32 0.0001 21.56
#Gene expression levels were assayed using the Affymetrix GeneChip Human Gene 1.0 ST Array.
*SOX11 siRNA vs. negative control siRNA transfected Granta 519 cells. Data analysis was done using the Partek Genomics suite software at a stringent threshold
(FDR,0.002, fold changes #21.5 or $1.5).
doi:10.1371/journal.pone.0014085.t001
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SOX11 downregulation (manuscript in preparation), in contrast to
what has been reported for neural cells [25]. However, since the
effect on gene expression in siRNA treated cells is transient, we
cannot exclude possible effects of SOX11 expression on cell survival
or proliferation in other experimental settings.
SOX11 is aberrantly expressed in MCL but the molecular
mechanism(s) responsible for its upregulation in lymphoid and
hematopoietic cells are not yet defined,incontrastto other celltypes.
InchickenneuralcellsoverexpressionofNgn2andAscl1upregulates
Sox11 while the transcriptional repressors Id1 and REST/NRSF
downregulates its expression [11]. In the mouse embryonal neuronal
plate Sox11 was upregulated by FoxD5 and Notch signalling
[45,46]. SOX11 mRNA expression was also rapidly (within 3 hours)
upregulated after exposure of retinal microglia to 17beta-estradiol
[47]. Even though SOX11 is highly expressed in most MCL,
expression of SOX11 seems not to be dependent on the t(11;14)
since it is a feature of both cyclin D1 positive and cyclin D1 negative
cases [3]. Furthermore, SOX11 may be expressed in other
aggressive B cell lymphomas that lack cyclin D1.
In summary, we have used selective siRNA targeting and
downregulation of SOX11 to identify a set of SOX11 responsive
genes. Our results have been validated in primary MCL tumors
and freshly isolated lymphoma cells. Three of the identified genes,
DBN1, SETMAR and HIG2, were found to be directly targeted
by the SOX11 protein in MCL.
Materials and Methods
Ethical Permission
This study was approved by the Ethical Committe at the
Karolinska Institutet, and performed according to the principles
Table 3. Validation of SOX11 siRNA downregulated genes in
a series of SOX11+ and SOX11- MCL
a).
probeset gene symbol Spearman ratio # p value#
204915_s_at*** SOX11 1 0
204914_s_at*** SOX11 0.95 1.35E-11
204913_s_at*** SOX11 0.93 4.46E-10
201310_s_at ** C5orf13 0.84 1.33E-06
201309_x_at ** C5orf13 0.78 1.97E-05
230424_at ** C5orf13 0.78 2.16E-05
238411_x_at C5orf13 0.29 0.18
203744_at ** HMGB3 0.82 3.10E-06
225601_at ** HMGB3 0.79 1.23E-05
202806_at ** DBN1 0.81 4.12E-06
217025_s_at * DBN1 0.67 6.06E-04
214051_at ** MGC39900 0.73 1.15E-04
206554_x_at * SETMAR 0.71 1.95E-04
1554059_at* SETMAR 0.45 0.03
1554060_s_at* SETMAR 0.43 0.05
209790_s_at * CASP6 0.70 2.55E-04
211464_x_at* CASP6 0.46 0.03
209118_s_at * TUBA1A 0.69 3.63E-04
226157_at* TFDP2 0.62 0.00
203588_s_at* TFDP2 0.62 0.00
203589_s_at* TFDP2 0.51 0.01
217970_s_at * CNOT6 0.50 0.02
222476_at CNOT6 0.11 0.64
205347_s_at * TMSB15A 0.46 0.03
209772_s_at* CD24 0.46 0.03
208650_s_at* CD24 0.44 0.04
208651_x_at CD24 0.39 0.07
216379_x_at CD24 0.36 0.10
209771_x_at CD24 0.36 0.10
227310_at* ADSS 0.46 0.03
221761_at ADSS -0.29 0.19
218507_at * HIG2 0.44 0.04
1554452_a_at * HIG2 0.44 0.04
213135_at * TIAM1 0.43 0.04
206409_at TIAM1 0.17 0.44
225351_at * FAM45A 0.44 0.04
1563919_a_at FAM45A 0.17 0.46
1563920_at FAM45A -0.06 0.79
204569_at ICK 0.40 0.06
1552837_at ICK 0.18 0.43
212364_at MYO1B -0.30 0.17
212365_at MYO1B -0.12 0.58
203236_s_at LGALS9 0.11 0.64
219676_at ZSCAN16 0.22 0.34
a)Data retrieved from (GSE15455) representing 7 indolent and 15 conventional MCL.
#The values were first tested for normal distribution. At the 0.05 level, all SOX11
data were not drawn from a normally distributed population, so we used
Spearman rank correlation coefficient. The Spearman ratio represents the
correlation between the values from SOX11 probe set 204915_s_at and the
probesets of the selected genes. 2-tailed test of significance was used.
*Moderate correlation (correlation coefficient 0.4–0.7);
**High correlation (correlation coefficient 0.7–0.9);
***Very high correlation (correlation coefficient 0.9–1.0).
doi:10.1371/journal.pone.0014085.t003
Table 2. Validation of SOX11 siRNA downregulated genes in
a dataset of 16 primary MCL
a).
Probe set Gene symbol Spearman ratio# p-value#
204915_s_at *** SOX11 1.00 0.00
206554_x_at * SETMAR 0.56 0.02
218507_at * HIG2 0.57 0.02
202806_at * DBN1 0.52 0.03
213996_at YPEL1 0.44 0.08
219897_at RNF122 20.37 0.16
208650_s_at CD24 20.34 0.20
208651_x_at CD24 0.13 0.63
209771_x_at CD24 20.12 0.66
209772_s_at CD24 0.03 0.91
216379_x_at CD24 20.07 0.78
203236_s_at LGALS9 0.19 0.48
201709_s_at NIPSNAP1 20.16 0.55
201708_s_at NIPSNAP1 0.11 0.70
204569_at ICK 20.11 0.68
a)Data from reference (51) representing 16 SOX11+ MCL.
#The values were first tested for normal distribution. At the 0.05 level, all SOX11
data were not drawn from a normally distributed population, so we used
Spearman rank correlation coefficient. The Spearman ratio represents the
correlation between the values from SOX11 probe set 204915_s_at and the
probesets of the selected genes. 2-tailed test of significance was used.
*Moderate correlation (correlation coefficient 0.4–0.7);
***Very high correlation (correlation coefficient 0.9–1.0).
doi:10.1371/journal.pone.0014085.t002
SOX11 Target Genes in MCL
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written informed consent to participate in the study.
Patient Samples
Eight samples of tumor cells were collected from 6 patients
diagnosed with cyclin D1+ MCL at the Department of Pathology
(Karolinska University Hospital Huddinge, Sweden) (Table 4).
Tumor cells were isolated from different tissues (bone marrow,
blood, lymph node, spleen, pleural exudate), viability frozen in
RPMI 1640 medium containing 10% DMSO and 40% FBS and
stored at -135uC.
Figure 3. Reduced expression of SETMAR and DBN1 in
response to SOX11siRNA. Analysis by qRT-PCR confirms downreg-
ulation of DBN1 and SETMAR (A) in SOX11 siRNA treated Granta 519
cells. (B) Expression of SOX11, TUBB3, SETMAR and DBN1 in the JeKo
cell line was evaluated after transfection with either 100 pmol SOX11
siRNA or control siRNA. mRNA levels were measured by quantitative RT-
PCR 20 hours after electroporation. Error bars show standard deviation
of 4 independent experiments. * P,0.05, **P,0.01.
doi:10.1371/journal.pone.0014085.g003
Figure 4. Expression of DBN1 correlates to SOX11 expression
in primary MCL cells and MCL cell lines. The expression values of
SOX11, DBN1 or SETMAR were analyzed by quantitative RT-PCR. The
threshold cycle (Ct) of the gene against the Ct of b actin was
determined by subtraction. All values were first tested for normal
distribution, and then the Pearson correlation coefficients and P value
were calculated. m MCL cell lines Granta 519, Rec1 and JeKo;N primary
MCL patients.
doi:10.1371/journal.pone.0014085.g004
Table 4. Isolated primary MCL cells from 6 patients
a).
Sample
number
Patient
age sex tissue
tumor cell
content#
A1 82 M blood 86%
A2 82 M pleural exudate 95%
B1 77 F blood 89%
B2 77 F bone marrow 92%
C 69 M spleen 80%
D 73 M spleen 88%
E 77 M lymph node 85%
F 66 M blood 69%
a)In two patients (A and B) tumor cells from different tissues were retrieved and
analyzed separately.
#Percentage of tumor cells as determined by flow cytometry.
doi:10.1371/journal.pone.0014085.t004
Figure 5. SOX11 protein directly targets DBN1, SETMAR and
HIG2. ChIP assay of SOX11 protein binding to the selected three genes.
Immunoprecipitated DNA was analyzed by quantitative RT-PCR for two
different primers as described in material and method. TSS: primer
designed close to transcription start site (TSS) and DT: primer distal
(,2 kb) to the TSS. Columns represent the mean of fold enrichment of
DBN1, SETMAR or HIG2 relative to IgG control. Error bars show standard
deviation of 3 independent experiments.* P,0.05, ** P,0.01 compared
to the IgG control.
doi:10.1371/journal.pone.0014085.g005
SOX11 Target Genes in MCL
PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e14085Cell Lines
Granta 519, Rec1, JeKo, JVM2 cell lines and primary cells were
obtained and cultured as previously described [48]. In short, cell
lines were maintained in culture medium (RPMI 1640, supple-
mented with 10% fetal bovine serum (FBS) and 50 mg/ml
gentamicin (all from Invitrogen, Carlsbad, CA)) under standard
conditions (humidified atmosphere, 95% air, 5% CO2,3 7 uC). The
cells were maintained between 3610
5 and 1.5610
6/ml. Culture
medium was changed twice weekly.
siRNA and Transient Transfection
Two silence H select pre-designed SOX11 siRNAs, S13312 and
S224667, and one non-targeting silenceH select Negative Control
#1 siRNA were obtained from Ambion (Ambion, Austin, TX).
siRNA S13312, used in most experiments had the sense targeting
sequence (59-39): GACCUGAUGUUCGACCUGAtt. Results
were confirmed using S224667 with the sense targeting sequence
(59-39): GGAGCUGAGCGAGAUGAUCtt. Freeze-dried siRNAs
were suspended in nuclease-free water (Ambion, Applied Biosys-
tem, Austin, TX) in a final concentration of 50 mM. Transient
transfection were performed on an Amaxa Nucleofection Device
(Lonza Cologne AG, Cologne, Germany) according to the
manufacturer’s instruction. In brief, Granta 519 cells were split
at a density of 5610
5/ml in the medium 48 hours before
transfection. Thereafter, 4610
6 cells were collected and resus-
pended in 100 ml human cell line nucleofector solution C with 100
pmol of either SOX11 siRNA or control siRNA using the X-01
electroporation program. The two SOX11 siRNAs were tested for
their individual ability to knock down SOX11 expression. Both
siRNA sequences were able to knock down SOX11 expression by
80%-85% in Granta 519 cells.
RNA Isolation and Affymetrix GeneChip Human Gene 1.0
ST Array
Cells were harvested 20 hours after siRNA transfection. Total
RNA from individual transfection experiments in Granta 519 cells
(n=4) or patient samples (n=8) was extracted with Qiagen
RNeasy Plus Mini kit according to the instructions of the
manufacturer (Qiagen, Valencia, CA). RNA quantity was
measured using a NanoDrop (NanoDrop Technologies, Wilming-
ton, DE) set for RNA measurement (A260/A280 ratio). RNA
quality was assessed using an Agilent Bioanalyzer 2100 (Agilent
Technologies, Palo Alto, CA) and samples with high-quality RNA
were hybridized to Affymetrix GeneChip Human Gene 1.0 ST
arrays (Affymetrix Inc. Santa Clara, CA) in accordance with the
Affymetrix standard protocol at the Bioinformatics and Expression
Analysis Core facility (BEA, Department of Biosciences and
Nutrition, Karolinska Institutet).
Gene Expression Data Analysis
The microarray image data were processed in the BEA core
facility according to standard procedures. CEL data was analyzed
with Partek Genomic Suite vs 6.5 (Partek Inc., St. Louis, MO)
which can normalize and process multiple datasets simultaneously.
Data normalization was performed by Robust Multiarray Analysis
algorithm (RMA). Statistical differences were examined using one
way ANOVA. Significant probesets were defined with a p-value
cutoff significant with a False Discovery Rate (FDR) of ,0.002,
and a fold-change (FC) equal or greater than 1.5(FC$1.5) for
upregulated genes and equal or less than 21.5(FC#1.5) for
downregulated genes, respectively.
Gene expression values for the selected genes were retrieved
from two primary array databases. Our previously published gene
expression analysis included 16 MCL tumor samples, all
expressing cyclin D1 and SOX11 [49]. We also retrieved data
from a recently published study from [19] which included 7
indolent, SOX11 negative MCL and 15 conventional, SOX11
positive MCL (http://www.ncbi.nlm.nih.gov/geo/with the GSE
accession number GSE16455).
cDNA Synthesis and Real-time Quantitative RT-PCR
cDNA was generated according to the protocol for Omniscript
Reverse Transcription (Qiagen, GmbH, Hilden, Germany). 2 mgo f
RNA was used in conjunction with Oligo(dT) primer and 20 mlo f
cDNA was generated. 1 ml of cDNA was added to qPCR Kit
Platinum SYBR Green qPCR SuperMix-UGD with FITC
(Invitrogen) according to the manufacturer’s instructions, run in
triplicate on a CFX96 Real-time System (C1000 Thermal Cycler,
BIO-RAD, city, CA). The following primers were used: SOX11,
59-CATGTAGACTAATGCAGCCATTGG-39 and 59-CACGG-
AGCACGTGTCAATTG-39; SOX4, 59- CAGCCCCTAATT-
TCTCCATGTT and 59- GGTGGCAGGTTAAGGGATACTG;
SOX12, 59- CCCAGGTCCACCCTCAGTAC and 59- CGAG-
AGTCTTCCTGCCATCAC; SETMAR, 59-GCGGAAGCGGC-
AAAGAC-39 and 59-GCCTCAGGCTTCTCCTTAAACTC-39;
DBN1, 59-GCCCCACCTGCTAACCAA-39 and 59-GTGATT-
GACTGAAGTACCCCTCACT-39; TUBB3,59- GGAGCGGAT-
CAGCGTCTACT-39 and 59-GCTCGAGGCACGTACTTGT-
G-39; b-actin, 59-AAAGACCTGTACGCCAACACA-39 and 59-
AGTACTTGCGCTCAGGAGGA-39. The cycle parameters used
was: 50uC 2 min, 95uC 2 min, followed by 40 cycles of 95uC for 15
seconds and 59uC for 30 seconds. Ct values (Threshold cycles) were
obtained from amplification of SOX11, SOX4, SOX12, SET-
MAR, DBN1, TUBB3 and b-actin. The DCt value was calculated
by subtracting the Ct value of b-actin from the Ct value of target
gene. A DDCt value was then calculated by subtracting the DCt
value for siRNA condition from the DCt value for control condition
with relative fold increase (RFI) reported as 2
2DDCt.
Western blotting
Western blotting was performed as described previously [4].
The blotted membranes were probed with rabbit anti-human
SOX11 (HPA000536, Atlas Antibodies, Uppsala, Sweden), and
antibodies to tubulin (SC 8035, Santa Cruz Biotechnology, Santa
Cruz, CA) or actin (A4700, Sigma, Saint Louis, MO) was used as
loading controls. Antibody binding was detected by enhanced
chemoluminescence using SupersignalWest Pico (Pierce Biotech-
nology, Shelton) CTchemiluminescent substrate.
Chromatin immunopreciption (ChIP)
Granta 519 cells were split at a density of 5610
5/ml in the
medium and cultured for 72 hours. Thereafter, 2610
7 cells were
collected and crosslinked with 1% formaldehyde for 10 min.
Cross-linking was quenched by adding 125 mM glycine and cells
were washed with cold PBS, harvested and resuspended in lysis
buffer containing protease inhibitors cocktail (Roche, Mannheim,
Germany) and sonicated 15 min for three times. The soluble
chromatin was collected by centrifugation and the supernatants
were incubated with 30 ml protein A/G Sepharose (50% slurry;
GE Healthcare Bio-Sciences Corp., Uppsala, Sweden) under
gentle agitation over night at 4uC. The supernatant was
transferred to a new microcentrifuge tube, followed by immuno-
precipitation with 1 mg of anti-SOX11 antibody and non-immune
rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) as control
at 4 C overnight. Protein A/G Sepharose (20 ml of a 50% slurry)
was then added and incubated for 1.5–2 h. The pellets were
successively washed with different buffer as previously described
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tion at 65uC in 120 ml elution buffer [TE; 1% SDS]. DNA was
purified using a PCR purification kit (QIAGEN, Valencia, CA)
and eluted in 50 ml of elution buffer. The immunoprecipitated
DNA was amplified by real-time PCR using Fast SYBR Green
Master Mix (Applied Biosystems, Warrington,UK) Two pairs of
primers were designed for DBN1, SETMAR and HIG2 with one
primer designed close to transcription start site (TSS) and one
distal (,2 kb) to the TSS (DT).
The primer pairs used are as follows:
DBN1 TSS forward: 59-TGAGGTGGAAGGATGTTTGCT-39;
Reverse: 59-CGGCGGTAAGGGAGTCACT-39.
DBN1 DT forward: 59-CCCTGCCGTGGGAGTCT-39;R e v e r s e :
59-TCCCAGAGGAGTCCCAAGTAGA-39.
SETMAR TSS forward: 59-GGGAGCCAGACCCAAAAAGT-
39; Reverse: 59-TTCTCAGGAGTGGCCTGGAA-39.
SETMAR DT forward: 59-AGAAAGATACAGAGAAGG-
GACTACTTGAG-39; Reverse: 59-TTCTTGTATCTCCAGT-
GCCTTTACC-39.
HIG2 TSS forward: 59-TCACTCCAGAACACAATGACT-
CAA-39; Reverse: 59-CGCGGAGCTGTTTCCAAA-39.
HIG2 DT forward: 59-TTTCCAACTGGCATGACCTTT-39;
Reverse: 59-GCACCTCTCCAACAATTCTTTCTC-39.
Statistical Analysis
Quantitative RT-PCR data were statistically analyzed using
paired t -test with P values ,0.05 as statistical significance. The
correlation between SOX11 and other genes as well as the
expression differences among MCL were analyzed with the
Spearman’s rank correlation coefficient test or Pearson correlation
coefficient for qRT-PCR results using Origin 8 software
(OriginLab, MA USA) using Origin 8 software. 2-tailed test for
significance was used.
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